A retrospective cohort study of patients with stomach and liver cancers: the impact of comorbidity and ethnicity on cancer care and outcomes

BMC Cancer

Diana Sarfati²  Jason Gurney²  James Stanley¹  Jonathan Koea³ 

[1] University of Otago Wellington, PO Box 7343, Wellington 6242, New Zealand

[2] Department of Public Health, University of Otago Wellington, PO Box 7343, Wellington 6242, New Zealand

[3] Waitemata District Health Board, Takapuna, Auckland, New Zealand

关键词: Survival;    New Zealand;    Māori;    Gastric neoplasms;    Hepatic neoplasms;    Cancer;    Ethnicity;    Comorbidity;   

Others  :  1120224
DOI  :  10.1186/1471-2407-14-821

 received in 2014-07-04, accepted in 2014-10-27,  发布年份 2014

【 摘 要 】

Background

Comorbidity has an adverse impact on cancer survival partly through its negative impact on receipt of curative treatment. Comorbidity is unevenly distributed within populations, with some ethnic and socioeconomic groups having considerably higher burden. The aim of this study was to investigate the inter-relationships between comorbidity, ethnicity, receipt of treatment, and cancer survival among patients with stomach and liver cancer in New Zealand.

Methods

Using the New Zealand Cancer Registry, Māori patients diagnosed with stomach and liver cancers were identified (n = 269), and compared with a randomly selected group of non-Māori patients (n = 255). Clinical and outcome data were collected from medical records, and the administrative hospitalisation and mortality databases. Logistic and Cox regression modelling with multivariable adjustment were used to examine the impacts of ethnicity and comorbidity on receipt of treatment, and the impact of these variables on all-cause and cancer specific survival.

Results

More than 70% of patients had died by two years post-diagnosis. As comorbidity burden increased among those with Stage I-III disease, the likelihood that the patient would receive curative surgery decreased (e.g. C3 Index score 6 vs 0, adjusted OR: 0.32, 95% CI 0.13-0.78) and risk of mortality increased (e.g. C3 Index score 6 vs 0, adjusted all-cause HR: 1.44, 95% CI 0.93-2.23). Receipt of curative surgery reduced this excess mortality, in some cases substantially; but the extent to which this occurred varied by level of comorbidity. Māori patients had somewhat higher levels of comorbidity (34% in highest comorbidity category compared with 23% for non-Māori) and poorer survival that was not explained by age, sex, site, stage, comorbidity or receipt of curative surgery (adjusted cancer-specific HR: 1.36, 95% CI 0.97-1.90; adjusted all-cause HR: 1.33, 95% CI 0.97-1.82). Access to healthcare factors accounted for 25-36% of this survival difference.

Conclusions

Patients with comorbidity were substantially less likely to receive curative surgery and more likely to die than those without comorbidity. Receipt of curative surgery markedly reduced their excess mortality. Despite no discernible difference in likelihood of curative treatment receipt, Māori remained more likely to die than non-Māori even after adjusting for confounding and mediating variables.

【 授权许可】

   
2014 Sarfati et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Extermann M: Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol 2000, 35(3):181-200.
• [2]Extermann M: Interaction between comorbidity and cancer. Cancer Control 2007, 14(1):13-22.
• [3]Gijsen R, Hoeymans N, Schellevis FG, Ruwaard D, Satariano WA, van den Bos GA: Causes and consequences of comorbidity: a review. J Clin Epidemiol 2001, 54(7):661-674.
• [4]Satariano WA, Silliman RA: Comorbidity: implications for research and practice in geriatric oncology. Crit Rev Oncol Hematol 2003, 48(2):239-248.
• [5]Yancik R, Ershler W, Satariano W, Hazzard W, Cohen HJ, Ferrucci L: Report of the national institute on aging task force on comorbidity. J Gerontol A Biol Sci Med Sci 2007, 62(3):275-280.
• [6]Blanco JAG, Toste IS, Alvarez RF, Cuadrado GR, Gonzalvez AM, Martin IJG: Age, comorbidity, treatment decision and prognosis in lung cancer. Age Ageing 2008, 37(6):715-718.
• [7]Chen RC, Royce TJ, Extermann M, Reeve BB: Impact of age and comorbidity on treatment and outcomes in elderly cancer patients. Semin Radiat Oncol 2012, 22(4):265-271.
• [8]Coebergh JWW, Janssen-Heijnen MLG, Razenberg PPA: Prevalence of co-morbidity in newly diagnosed patients with cancer: A population-based study. Crit Rev Oncol Hematol 1998, 27(2):97-100.
• [9]Koppie TM, Serio AM, Vickers AJ, Vora K, Dalbagni G, Donat SM, Herr HW, Bochner BH: Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. Cancer 2008, 112(11):2384-2392.
• [10]Lash TL, Thwin SS, Horton NJ, Guadagnoli E, Silliman RA: Multiple informants: a new method to assess breast cancer patients’ comorbidity. Am J Epidemiol 2003, 157(3):249-257.
• [11]Lee L, Cheung WY, Atkinson E, Krzyzanowska MK: Impact of comorbidity on chemotherapy use and outcomes in solid tumors: a systematic review. J Clin Oncol 2011, 29(1):106-117.
• [12]Newschaffer CJ, Penberthy LT, Desch CE, Retchin SM, Whittemore M: The effect of age and comorbidity in the treatment of elderly women with nonmetastatic breast cancer. Arch Intern Med 1996, 156(1):85-90.
• [13]Sarfati D, Hill S, Blakely T, Robson B, Purdie G, Dennett E, Cormack D, Dew K: The effect of comorbidity on the use of adjuvant chemotherapy and survival from colon cancer: A retrospective cohort study. BMC Cancer 2009, 9:16. BioMed Central Full Text
• [14]Tammemagi C, Nerenz D, Neslund-Dudas C, Feldkamp C, Nathanson D: Comorbidity and survival disparities among black and white patients with breast cancer. JAMA 2005, 294(14):1765-1772.
• [15]Etzioni DA, El-Khoueiry AB, Beart RW: Rates and predictors of chemotherapy use for stage III colon cancer. Cancer 2008, 113:3279-3289.
• [16]Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B: Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 2012, 380(9836):37-43.
• [17]Moulton P, McDonald L, Muus K, Knudson A, Wakefield M, Ludtke R: Prevalence of chronic disease among American Indian and Alaska Native elders. University of North Dakota, Centres for Rural Health, School of Medicine and Health Sciences; 2005. (http://ruralhealth.und.edu/projects/nrcnaa/pdf/chronic_disease1005.pdf webcite)
• [18]Robson B, Harris R (Eds): Hauora: Maori Standards of Health IV. A study of the years 2000–2005. Wellington: Te Ropu Rangahau Hauora a Eru Pomare; 2007.
• [19]Valery PC, Coory M, Stirling J, Green AC: Cancer diagnosis, treatment, and survival in Indigenous and non-Indigenous Australians: a matched cohort study. Lancet 2006, 367(9525):1842-1848.
• [20]Hill S, Sarfati D, Blakely T, Purdie G, Chen J, Dennett E, Cormack D, Cunningham R, Dew K, McCreanor T, Kawachi I: Survival disparities in Indigenous and non-Indigenous New Zealanders with colon cancer: the role of patient comorbidity, treatment and health service factors. J Epidemiol Comm Health 2010, 64:117-123.
• [21]Rachet B, Woods LM, Mitry E, Riga M, Cooper N, Quinn MJ, Steward J, Brenner H, Esteve J, Sullivan R, Coleman MP: Cancer survival in England and Wales at the end of the 20th century. Br J Cancer 2008, 99:S2-S10.
• [22]Ward E, Jemal A, Cokkinides V, Cardinez C, Ghafoor A, Thun M: Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin 2004, 54:78-93.
• [23]Sheppard AJ, Chiarelli AM, Marrett LD, Singh GK, Cardinez C, Ghafoor A, Thun M: Stage at diagnosis and comorbidity influence breast cancer survival in First Nations women in Ontario, Canada. Cancer Epidemiol Biomarkers Prev 2011, 20(10):2160-2167.
• [24]Allard JE, Maxwell GL: Race disparities between black and white women in the incidence, treatment, and prognosis of endometrial cancer. Cancer Control 2009, 16(1):53-56.
• [25]Braithwaite D, Tammemagi CM, Moore DH, Ozanne EM, Hiatt RA, Belkora J, West DW, Satariano WA, Liebman M, Esserman L: Hypertension is an independent predictor of survival disparity between African-American and white breast cancer patients. Int J Cancer 2009, 124(5):1213-1219.
• [26]Cook LS, Nelson HE, Cockburn M, Olson SH, Muller CY, Wiggins CL: Comorbidities and endometrial cancer survival in Hispanics and non-Hispanic whites. Cancer Causes Control 2013, 24(1):61-69.
• [27]Holmes L Jr, Chan W, Jiang Z, Ward D, Essien EJ, Du XL: Impact of androgen deprivation therapy on racial/ethnic disparities in the survival of older men treated for locoregional prostate cancer. Cancer Control 2009, 16(2):176-185.
• [28]Putt M, Long JA, Montagnet C, Silber JH, Chang VW, Kaijun L, Schwartz JS, Pollack CE, Wong Y-N, Armstrong K: Racial differences in the impact of comorbidities on survival among elderly men with prostate cancer. Med Care Res Rev 2009, 66(4):409-435.
• [29]Yang R, Cheung MC, Byrne MM, Huang Y, Nguyen D, Lally BE, Koniaris LG: Do racial or socioeconomic disparities exist in lung cancer treatment? Cancer 2010, 116(10):2437-2447.
• [30]Coker AL, Eggleston KS, Du XL, Ramondetta L: Ethnic disparities in cervical cancer survival among Medicare eligible women in a multiethnic population. Int J Gynecol Cancer 2009, 19(1):13-20.
• [31]Curtis E, Quale C, Haggstrom D, Smith-Bindman R: Racial and ethnic differences in breast cancer survival: how much is explained by screening, tumor severity, biology, treatment, comorbidities, and demographics? Cancer 2008, 112(1):171-180.
• [32]Hines RB, Shanmugam C, Waterbor JW, McGwin G Jr, Funkhouser E, Coffey CS, Posey J, Manne U: Effect of comorbidity and body mass index on the survival of African-American and Caucasian patients with colon cancer. Cancer 2009, 115(24):5798-5806.
• [33]Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893-2917.
• [34]Statistics New Zealandhttp://www.stats.govt.nz/browse_for_stats/population/estimates_and_projections/subnational-ethnic-population-projections/north-and-south-islands.aspx webcite. Secondary http://www.stats.govt.nz/browse_for_stats/population/estimates_and_projections/subnational-ethnic-population-projections/north-and-south-islands.aspx webcite Accessed January 2014
• [35]Chamberlain J, Sarfati D, Cunningham R, Koea J, Gurney J, Blakely T: Incidence and management of hepatocellular carcinoma among Māori and non-Māori New Zealanders. Aust NZ J Public Health 2013, 37:520-526.
• [36]Salmond C, Crampton P, Atkinson J: NZDep 2006 Index of Deprivation User’s Manual. Wellington: University of Otago; 2007.
• [37]Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A: AJCC Cancer Staging Manual. 7th edition. New York: Springer; 2010.
• [38]Sarfati D, Gurney J, Stanley J, Salmond C, Crampton P, Dennett E, Koea J, Pearce N: Cancer-specific administrative data-based comorbidity indices provided valid alternative to Charlson and NHI indices. J Clin Oncol 2014, 67(5):586-595.
• [39]Sarfati D, Gurney J, Lim B, Bagheri N, Simpson A, Koea J, Dennett E: Identifying important comorbidity among cancer populations using administrative data: prevalence and impact on survival. Asia Pac J Clin Oncol 2013. doi:10.1111/ajco.12130
• [40]Desquilbet L, Mariotti F: Dose–response analyses using restricted cubic spline functions in public health research. Stat Med 2010, 29(9):1037-1057.
• [41]Fleming ST, Pursley HG, Newman B, Pavlov D, Chen K: Comorbidity as a predictor of stage of illness for patients with breast cancer. Med Care 2005, 43(2):132-140.
• [42]Terret C, Castel-Kremer E, Albrand G, Droz JP: Effects of comorbidity on screening and early diagnosis of cancer in elderly people. Lancet Oncol 2009, 10(1):80-87.
• [43]Adami HO, Hunter D, Trichopoulos D (Eds): Textbook of Cancer Epidemiology. 2nd edition. New York: Oxford University Press; 2008.
• [44]Keating NL, Landrum MB, Klabunde CN, Fletcher RH, Rogers SO, Doucette WR, Tisnado D, Clauser S, Kahn KL: Adjuvant chemotherapy for stage III colon cancer: do physicians agree about the importance of patient age and comorbidity? J Clin Oncol 2008, 26(15):2532-2537.
• [45]Krzyzanowska MK, Regan MM, Powell M, Earle CC, Weeks JC: Impact of patient age and comorbidity on surgeon versus oncologist preferences for adjuvant chemotherapy for stage III colon cancer. J Am Coll Surg 2009, 208(2):202-209.
• [46]Ring A: The influences of age and co-morbidities on treatment decisions for patients with HER2-positive early breast cancer. Crit Rev Oncol Hematol 2010, 76(2):127-132.
• [47]Hall WH, Jani AB, Ryu JK, Narayan S, Vijayakumar S: The impact of age and comorbidity on survival outcomes and treatment patterns in prostate cancer. Prostate Cancer Prostatic Dis 2005, 8(1):22-30.
• [48]Rieker RJ, Hammer E, Eisele R, Schmid E, Hogel J: The impact of comorbidity on the overall survival and the cause of death in patients after colorectal cancer resection. Langenbeck Arch Surg 2002, 387(2):72-76.
• [49]Gronberg BH, Sundstrom S, Kaasa S, Bremnes RM, Flotten O, Amundsen T, Hjelde HH, Plessen C, Jordhoy M: Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy. Eur J Cancer 2010, 46(12):2225-2234.
• [50]Gross CP, McAvay GJ, Guo Z, Tinetti ME: The impact of chronic illnesses on the use and effectiveness of adjuvant chemotherapy for colon cancer. Cancer 2007, 109(12):2410-2419.
• [51]Lemmens VEPP, Janssen-Heijnen MLG, Houterman S, Verheij KDGW, Martijn H, van de Poll-Franse L, Coebergh JWW: Which comorbid conditions predict complications after surgery for colorectal cancer? World J Surg 2007, 31(1):192-199.
• [52]LoConte NK, Smith M, Alberti D, Bozeman J, Cleary JF, Setala AN, Wodtke G, Wilding G, Holen KD: Amongst eligible patients, age and comorbidity do not predict for dose-limiting toxicity from phase I chemotherapy. Cancer Chemother Pharmacol 2010, 65(4):775-780.
• [53]Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB 3rd, Fuchs CS: Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol 2003, 21(3):433-440.
• [54]Peters TTA, van der Laan BFAM, Plaat BEC, Wedman J, Langendijk JA, Halmos GB: The impact of comorbidity on treatment-related side effects in older patients with laryngeal cancer. Oral Oncol 2011, 47(1):56-61.
• [55]Seymour MT, Thompson LC, Wasan HS, Middleton G, Brewster AE, Shepherd SF, O'Mahony MS, Maughan TS, Parmar M, Langley RE, Focus Investigators National Cancer Research Institute Colorectal Cancer Clinical Studies Group: Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet 2011, 377(9779):1749-1759.
• [56]Lemmens VE, Janssen-Heijnen ML, Verheij CD, Houterman S, van Driel OJ R, Coebergh JW: Co-morbidity leads to altered treatment and worse survival of elderly patients with colorectal cancer. Br J Surg 2005, 92(5):615-623.
• [57]Bellera C, Praud D, Petit-Moneger A, McKelvie-Sebileau P, Soubeyran P, Mathoulin-Pelissier S: Barriers to inclusion of older adults in randomised controlled clinical trials on Non-Hodgkin’s lymphoma: a systematic review. Cancer Treat Rev 2013, 39(7):812-817.
• [58]Fortin M, Dionne J, Pinho G, Gignac J, Almirall J, Lapointe L: Randomized controlled trials: do they have external validity for patients with multiple comorbidities? Ann Fam Med 2006, 4(2):104-108.
• [59]Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS: Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Eng J Med 1999, 341(27):2061-2067.
• [60]Murthy VH, Krumholz HM, Gross CP: Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 2004, 291(22):2720-2726.
• [61]Scher KS, Hurria A: Under-representation of older adults in cancer registration trials: known problem, little progress. J Clin Oncol 2012, 30(17):2036-2038.
• [62]Brewer N, Borman B, Sarfati D, Jeffreys M, Fleming ST, Cheng S, Pearce N: Does comorbidity explain the ethnic inequalities in cervical cancer survival in New Zealand? A retrospective cohort study. BMC Cancer 2011, 11:132. BioMed Central Full Text
• [63]Hill S, Sarfati D, Blakely T, Robson B, Purdie G, Dennett E, Cormack D, Dew K, Ayanian JZ, Kawachi I: Ethnic disparities in treatment of Māori and non-Māori New Zealanders with colon cancer. Cancer 2010, 116:3205-3214.
• [64]Jeffreys M, Stevanovic S, Tobias M, Lewis C, Ellison-Loschmann L, Pearce N, Blakely T: Ethnic differences in cancer survival in New Zealand: linkage study. Am J Public Health 2005, 95(5):834-837.
• [65]Stevens W, Stevens G, Kolbe J, Cox B: Ethnic differences in the management of lung cancer in New Zealand. J Thorac Oncol 2008, 3(3):237-244.